English 
简体中文 Fenfluramine (Fen)
1) The main possible mechanism: Activates specific serotonin receptors (including 5-HT1D, 5-HT2A, and 5-HT2C receptors) and also acts on sigma-1 receptors.
2) Therapeutic indications: Adjuvant treatment of Dravet Syndrome and Lennox-Gastaut Syndrome in patients 2 years of age and older.
3) Warning: Due to the possible serious side effects (valvular heart disease and pulmonary hypertension), its use is not recommended in most cases except for the above indications.
4) Dosage for children: Click to view the dosage for children of different ages and weights.
5) Major adverse reactions in children: Common symptoms include loss of appetite, weight loss, fatigue, lethargy, vomiting, diarrhea, ataxia, etc. Additionally, this drug may cause valvular heart disease and pulmonary hypertension.
6) Interaction with other anti-epileptic drugs: Stiripentol plus clobazam (with or without valproate sodium) may increase fenfluramine plasma concentrations.
7) Interaction with non-anti-epileptic drugs: Strong CYP1A2, CYP2B6, or CYP3A inducers (e.g., rifampicin) may decrease fenfluramine plasma concentrations.Strong CYP1A2 or CYP2D6 inhibitors (e.g., fluvoxamine (strong CYP1A2 inhibitor), paroxetine (strong CYP2D6 inhibitor)) may increase fenfluramine plasma concentrations.